Gastrointestinal Cancers

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Both laparoscopic wedge and endoscopic resection are safe and feasible treatment approaches for patients with gastric gastrointestinal stromal tumors.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

This marks the second FDA approval of Tevimbra this year.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

Patients with locally advanced gastric cancers saw complete response rates of 18.3% from camrelizumab and rivoceranib plus chemotherapy.

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved relapse-free survival.

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA.

I initially put off a colonoscopy due to gastroesophageal reflux disease, but after a positive home screening test, I underwent the procedure and was diagnosed with stage 3 rectal cancer.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

In the first 15 patients, radiofrequency ablation was shown to reduce pain scores in most patients with pancreatic cancer.

Stivarga improved survival and delayed disease progression in patients with refractory advanced gastric and esophagogastric junction cancer.

The FDA has approved Vyloy for patients with HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma with CLDN18.2-positive tumors.

Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active surveillance.

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved survival versus surgery alone.

Several colleagues, patients and caregivers nominated Jill May, B.S.N., RN, OCN, for the 2024 Extraordinary Healer Award for her dedicating to caring for those with gastrointestinal cancers.

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal stromal tumors.

I invited my family to gather with me and celebrate four years of being cancer-free.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar.